Stock PTCT PTC THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
33.62 USD -1.58% Intraday chart for PTC Therapeutics, Inc. +33.36% +21.99%
04-30 North American Morning Briefing : More Earnings -2- DJ
04-29 Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Sector Update: Health Care
PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results
PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
PTC Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2024
PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency
PTC Therapeutics Shares Jump Following Q4 Results
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Sector Update: Health Care Stocks Higher Friday Afternoon
Sector Update: Health Care Stocks Mixed Premarket Friday
Sector Update: Health Care
PTC Therapeutics' Muscle Disorder Drug Gets Negative Opinion From European Medicines Agency
Europe to withdraw PTC Therapeutics' rare muscle disorder drug
PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn Following Re-examination Procedure
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTCT Stock
  4. News PTC Therapeutics, Inc.
  5. Other languages